Varicella and varicella vaccination

被引：0
作者：
M. Knuf
P. Habermehl
机构：
[1] Kinderklinik und Kinderpoliklinik, Johannes Gutenberg-Universitat Mainz, Mainz
[2] Kinderklinik und Kinderpoliklinik, Johannes Gutenberg-Universitat Mainz, 55101 Mainz
来源：
Monatsschrift Kinderheilkunde | 2004年 / 152卷 / 9期
关键词：
Epidemiology; Prevention; Varicella;
D O I：
10.1007/s00112-004-1006-0
中图分类号：
学科分类号：
摘要：
Considering about 750.000 cases of chickenpox each year in Germany - most of these cases occur in children - varicella is the most frequent infectious disease preventable by vaccination. It is estimated that up to 40.000 complications from chickenpox occur annually in adults and children. Complications of varicella include mainly bacterial superinfection, otitis media, pneumonia and bronchitis, but cerebelitis, meningitis and encephalitis also occur. Adults and children in their first year of life are at the highest risk for complications. The large numbers of cases and complications clearly show that varicella has a high impact on the German national economy. Universal mass vaccination against chickenpox in Germany is expected to significantly reduce the morbidity and yield savings in overall healthcare costs amounting to several million Euros. There has been a general varicella vaccination recommendation for the last 8 years in the USA, which confirms the safety and high efficacy of the vaccine.
引用
收藏
页码：1015 / 1029
页数：14
相关论文
共 14 条
  • [1] Arvin A.M., Varicella vaccine: Genesis, efficacy, and attenuation, Virology, 284, 2, pp. 153-158, (2001)
  • [2] Banz K., Wagenpfeil S., Neiss A., Et al., The costeffectiveness of routine childhood varicella vaccination in Germany, Vaccine, 21, pp. 1256-1267, (2003)
  • [3] Immunisation Coverage in the US, (2002)
  • [4] Hammerschmidt T., Goertz A., Wagenpfeil S., Et al., Validation of health economic models: The example of EVITA, Value Health, 6, pp. 551-559, (2003)
  • [5] Klose T., Banz K., Wagenpfeil S., Et al., Varicella vaccination in Germany: An analysis with focus on the impact of coverage on age-shifts and the elimination of the disease, Eur J Public Health, 12, SUPPL., (2002)
  • [6] Kuter B.J., Weibel R.E., Guess H.A., Et al., Oka/Merck varicella vaccine in healthy children: Final report of a 2-year efficacy study and 7-year follow up study, Vaccine, 9, pp. 643-647, (1991)
  • [7] Kuter B.J., Matthews H., Shinefield H., Et al., Ten year follow-up of healthy children who received one or two injections of varicella vaccine, Pediatr Infect Dis J, 23, 2, pp. 132-137, (2004)
  • [8] Sengupta N., Breuer J., Schmitt H.J., Et al., Vaccination against varicella: How best can we reduce the burden of disease? Consensus paper from the Society of Independent European Vaccination Experts (SIEVE), Lancet, (2004)
  • [9] Seward J.F., Watson B.M., Peterson C.L., Et al., Varicella disease after introduction of varicella vaccine in the United States, 1995-2000, JAMA, 287, pp. 606-611, (2002)
  • [10] Sharrar R.G., LaRussa P., Galea S.A., Et al., The postmarketing safety profile of varicella vaccine, Vaccine, 19, pp. 916-923, (2001)
12